ESR1 and neoplasm: The fact that we observed robust antagonism in CTC174 cells through reduced PGR mRNA expression and tumour growth inhibition at 100 mg/kg, approaching the levels achieved for AZD983337, supported our hypothesis that sufficient compound was penetrating the tumour to bind and antagonise ERα.